{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-323057","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2021-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.529180+00:00","generated_at":"2026-06-28T11:43:19.667309+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cytek Q3 revenue $34.4M (+37% YoY); net income $1.6M down from $6.5M","bullets":["Total revenue $34.4M, up 37% YoY; gross margin 62% (non-GAAP 64%).","Net income $1.6M, down from $6.5M YoY; non-GAAP net income $4.1M vs $6.7M.","Operating expenses $18.3M, up 106% YoY due to public company costs and R&D investment.","Cash $377M; installed base expanded to 970 instruments with 115 placements in Q3.","Announced acquisition of Tonbo Biosciences' cell analysis business to enhance reagent portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-323057","json":"https://secwatch.observer/filing/0001193125-21-323057.json","markdown":"https://secwatch.observer/filing/0001193125-21-323057.md","text":"https://secwatch.observer/filing/0001193125-21-323057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312521323057/0001193125-21-323057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312521323057/d257430d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:43:19.667309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}